Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Lyell Immunopharma, Inc. Common Stock

LYEL

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Last trade $13.81
Day change -$0.84 (-5.73%)
Day range $13.29 – $15.02
Volume 113,036
Market cap $469M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$469.03M
Price / earnings
—
Price / book
2.43×
Price / sales
31,268.68×
EV / sales
25,131.81×
EV / EBITDA
-1.94×

Profitability

Earnings per share
-$7.97
Return on assets
-93.17%
Return on equity
-132.4%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.02×
Quick ratio
4.02×
Cash ratio
1.99×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$139.97M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for LYEL, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$3K$4K$2K$6K$15K$8K$7K$11K
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$3K$4K$2K$6K$15K$8K$7K$11K
Selling, general and administrative$9.3M$9.58M$9.56M$10.62M$10.69M$9.79M$14.05M$14.52M
Research and development$40.9M$39.52M$36.6M$52.2M$28.17M$34.86M$43.45M$48.67M
Total operating expenses$48.3M$47.34M$44.26M$129.8M$37.27M$47.15M$57.37M$204.47M
Operating income-$48.3M-$47.34M-$44.26M-$129.79M-$37.25M-$47.14M-$57.37M-$204.46M
Interest expense$1.91M$2.18M$2.19M$0$3.27M$3.28M$3.86M$0
Income before taxes-$45.53M-$44.76M-$24.15M-$140.72M-$38.85M-$42.68M-$52.2M-$191.94M
Income taxes$0$0$0$0$0$0$0$0
Net income-$45.53M-$44.76M-$24.15M-$140.72M-$38.85M-$42.68M-$52.2M-$191.94M
Net income attributable to common shareholders-$45.53M-$44.76M-$24.15M-$140.72M-$38.85M-$42.68M-$52.2M-$191.94M
EBITDA-$46.24M-$45.12M-$41.93M-$61.06M-$34.69M-$42.56M-$53.93M-$60.95M
Basic earnings per share-$1.86-$1.92-$1.10-$6.85-$2.13-$2.89-$3.54-$13.71
Diluted earnings per share-$1.86-$1.92-$1.10-$6.85-$2.13-$2.89-$3.54-$13.71

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Wall Street Analysts See a 148.25% Upside in Lyell Immunopharma (LYEL): Can the Stock Really Move This High?

Lyell Immunopharma (LYEL) has gained 76.1% over the past four weeks and closed at $14.30. Wall Street analysts have set a mean price target of $35.50, indicating 148.3% upside potential. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions. However, the article cautions that analyst price targets can be misleading and should not be the sole basis for investment decisions.

GlobeNewswire Inc.

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

Lyell Immunopharma announced updated safety data for ronde-cel, its dual-targeting CD19/CD20 CAR T-cell therapy, showing no Grade ≥3 cytokine release syndrome and low Grade ≥3 neurotoxicity rates in over 100 patients with relapsed/refractory large B-cell lymphoma. Translational data revealed enhanced memory potential of CAR T cells and durable responses, particularly in patients with low antigen expression. The company expects pivotal trial data in mid-2027 with BLA submission to follow.

GlobeNewswire Inc.

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

Lyell Immunopharma announced positive safety data for LYL273, its GCC-targeted CAR T-cell therapy for metastatic colorectal cancer. Gastrointestinal prophylaxis significantly reduced Grade ≥2 diarrhea/colitis from 55% to 10%, with no Grade ≥3 cytokine release syndrome or neurotoxicity observed. The Phase 1 trial has been amended to Phase 1/2 design to enable seamless expansion into a potential pivotal Phase 2 trial, with an End-of-Phase 1 FDA meeting expected by end of 2026.

GlobeNewswire Inc.

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

Lyell Immunopharma closed an additional $50 million tranche from its $100 million equity private placement following achievement of a clinical milestone for rondecabtagene autoleucel (ronde-cel) in its PiNACLE pivotal trial for relapsed/refractory large B-cell lymphoma. The company also appointed Smital Shah as Chief Financial and Business Officer. With this funding, Lyell expects sufficient cash runway into Q2 2027.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 2, 20251-for-20reverse split